Oliver Sevilla, MD
Pulmonary Disease · Crystal River, FLNPI 1871567669
Payments from drug & device makers
Across 138 payments — averaging $46.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- GSK$663
- Boehringer Ingelheim$292
- Sanofi$259
- Genentech USA, Inc.$249
- Insmed, Inc.$148
- plus $1K from 19 others
What the payments were for
- Travel & lodging$1,12918%
- Food & beverage$2,74943%
- Education$2,50039%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $3,661 |
| GSK | 42 | $663 |
| Boehringer Ingelheim | 15 | $292 |
| Sanofi | 6 | $259 |
| Genentech USA, Inc. | 13 | $249 |
| Insmed, Inc. | 6 | $148 |
| Fujifilm Healthcare Americas Corporation | 2 | $146 |
| Pulmonx Corporation | 3 | $144 |
| Mylan Specialty L.p. | 8 | $132 |
| Grifols USA, LLC | 5 | $128 |
| AstraZeneca | 5 | $79 |
| Johnson & Johnson | 4 | $66 |
| Inogen, Inc. | 5 | $61 |
| Verona Pharma, Inc. | 3 | $58 |
| Jazz Pharmaceuticals Inc. | 2 | $53 |
| ZOLL Circulation Inc | 1 | $52 |
| Viatris Specialty LLC | 3 | $47 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| United Therapeutics Corporation | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
| Harmony Biosciences LLC | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Tactile Systems Technology Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,580
- FUJIFILM$111
- TRELEGY ELLIPTA$101
How this compares
$6,378 in reported general payments places this provider in the 55th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 196 | $235,160 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 92 | $122,144 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 91 | $89,144 |
| Spiriva RespimatTiotropium Bromide | 74 | $74,564 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 37 | $42,033 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $31,564 |
| Spiriva HandihalerTiotropium Bromide | 22 | $29,782 |
| Incruse ElliptaUmeclidinium Bromide | 34 | $20,888 |
| SymbicortBudesonide/Formoterol Fumarate | 40 | $15,132 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 245 | $10,750 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 21 | $10,704 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 27 | $8,921 |
| EliquisApixaban | 12 | $7,834 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $7,262 |
| Wixela InhubFluticasone Propion/Salmeterol | 25 | $2,620 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $663 | $379,323376 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $79 | $137,276132 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $292 | $127,301132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Crystal River
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
- Neal WarshoffLoxahatchee$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.